



# Human Lp(a) ELISA Kit

Assaypro LLC  
3400 Harry S Truman Blvd  
St. Charles, MO 63301  
T (636) 447-9175  
F (636) 395-7419  
[www.assaypro.com](http://www.assaypro.com)

For any questions regarding troubleshooting or performing the assay, please contact our support team at [support@assaypro.com](mailto:support@assaypro.com).

Thank you for choosing Assaypro.

## Assay Summary

**Step 1.** Add 50  $\mu$ l of Standard or Sample per well.  
Incubate 2 hours.

**Step 2.** Wash, then add 50  $\mu$ l of Biotinylated Antibody per well.  
Incubate 1 hour.

**Step 3.** Wash, then add 50  $\mu$ l of SP Conjugate per well.  
Incubate 30 minutes.

**Step 4.** Wash, then add 50  $\mu$ l of Chromogen Substrate per well.  
Incubate 10 minutes.

**Step 5.** Add 50  $\mu$ l of Stop Solution per well.  
Read at 450 nm immediately.

## Symbol Key



Consult instructions for use.





# AssayMax Human Lipoprotein(a) ELISA Kit

Catalog No. EL3001-1

*Sample protocol for reference only*

## Introduction

Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein particle formed by an assembly of LDL particles and apo(a) bound to apoB-100 component of LDL (1). Apo(a), the main constituent of Lp(a), has serine proteinase activity and is capable of autoproteolysis (2). Apo(a) has 4548 amino acids, variable sizes from 200 to 700 kDa, multiple isoforms, and structural homology with plasminogen (3-5). It competes with plasminogen for its binding site, inhibiting tissue-type plasminogen activator 1 and leading to reduced fibrinolysis (6). The mean Lp(a) protein level ranged from 78 to 175  $\mu\text{g/ml}$  depending on populations and the risk threshold is 300  $\mu\text{g/ml}$  (7-9). High levels of Lp(a) in the blood is a risk factor for myocardial infarction (MI), coronary heart disease (CHD), cerebrovascular disease (CVD), atherosclerosis, thrombosis, and stroke (10, 11).

## Principle of the Assay

The AssayMax Human Lp(a) ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for detection of human Lp(a) in **plasma, serum, urine, milk, CSF, and cell culture samples**. This assay employs a quantitative **sandwich enzyme immunoassay** technique that measures human Lp(a) in less than 4 hours. A polyclonal antibody specific for human Lp(a) has been pre-coated onto a 96-well microplate with removable strips. Lp(a) in standards and samples is sandwiched by the immobilized antibody and biotinylated polyclonal antibody specific for Lp(a), which is recognized by a streptavidin-peroxidase conjugate. All unbound material is then washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

## Caution and Warning

- Prepare all reagents (working diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this protocol. However, the user should determine the optimal dilution factor.

- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- This kit is for research use only.
- The kit should not be used beyond the expiration date.

## Reagents

- **Human Lp(a) Microplate:** A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human Lp(a).
- **Sealing Tapes:** Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- **Human Lp(a) Standard:** Human Lp(a) in a buffered protein base (90 ng, lyophilized).
- **Biotinylated Human Lp(a) Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against Lp(a) (140  $\mu$ l).
- **EIA Diluent Concentrate (10x):** A 10-fold concentrated buffered protein base (30 ml).
- **Wash Buffer Concentrate (20x):** A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- **Streptavidin-Peroxidase Conjugate (SP Conjugate):** A 100-fold concentrate (80  $\mu$ l).
- **Chromogen Substrate:** A ready-to-use stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml).
- **Stop Solution:** A 0.5 N hydrochloric acid to stop the chromogen substrate reaction (12 ml).

## Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Diluent (1x) may be stored for up to 30 days at 2-8°C.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

## Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm.
- Pipettes (1-20  $\mu\text{l}$ , 20-200  $\mu\text{l}$ , 200-1000  $\mu\text{l}$ , and multiple channel).
- Deionized or distilled reagent grade water.

## Sample Collection, Preparation and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x *g* for 10 minutes. Dilute samples 1:8000 into EIA Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x *g* for 10 minutes, and remove serum. Dilute samples 1:8000 into EIA Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **Cell Culture Supernatants:** Centrifuge cell culture media at 3000 x *g* for 10 minutes to remove debris. Collect supernatants and assay. Store samples at -20°C or below. Avoid repeated freeze-thaw cycles.
- **Urine:** Collect urine using sample pot. Centrifuge samples at 800 x *g* for 10 minutes. Dilute samples 1:4 into EIA Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **Milk:** Collect milk using sample tube. Centrifuge samples at 800 x *g* for 10 minutes. Dilute samples 1:4000 into EIA Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **CSF:** Collect cerebrospinal fluid (CSF) using sample tube. Centrifuge samples at 3000 x *g* for 10 minutes. Dilute samples 1:8 into EIA Diluent and assay. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.

***Refer to Sample Dilution Guidelines below for further instruction.***

<b>Guidelines for Dilutions of 1:100 or Greater</b> <i>(for reference only; please follow the protocol for specific dilution suggested)</i>	
<b>1:100</b>	<b>1:10000</b>
A) 4 µl sample : 396 µl buffer (100x) = 100 fold dilution  <i>Assuming the needed volume is less than or equal to 400 µl.</i>	A) 4 µl sample : 396 µl buffer (100x) B) 4 µl of A : 396 µl buffer (100x) = 10000 fold dilution  <i>Assuming the needed volume is less than or equal to 400 µl.</i>
<b>1:1000</b>	<b>1:100000</b>
A) 4 µl sample : 396 µl buffer (100x) B) 24 µl of A : 216 µl buffer (10x) = 1000 fold dilution  <i>Assuming the needed volume is less than or equal to 240 µl.</i>	A) 4 µl sample : 396 µl buffer (100x) B) 4 µl of A : 396 µl buffer (100x) C) 24 µl of B : 216 µl buffer (10x) = 100000 fold dilution  <i>Assuming the needed volume is less than or equal to 240 µl.</i>

## Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute the EIA Diluent Concentrate 1:10 with reagent grade water. Store for up to 30 days at 2-8°C.
- **Standard Curve:** Reconstitute the 90 ng of Human Lp(a) Standard with 1.8 ml of EIA Diluent to generate a 50 ng/ml standard stock solution. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting the standard stock solution (50 ng/ml) 1:2 with equal volume of EIA Diluent to produce 25, 12.5, 6.25, 3.125, and 1.563ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Any remaining solution should be frozen at -20°C and used within 15 days.

Standard Point	Dilution	[Lp(a)] (ng/ml)
P1	1 part Standard (50 ng/ml)	50.00
P2	1 part P1 + 1 part EIA Diluent	25.00
P3	1 part P2 + 1 part EIA Diluent	12.50
P4	1 part P3 + 1 part EIA Diluent	6.250
P5	1 part P4 + 1 part EIA Diluent	3.125
P6	1 part P5 + 1 part EIA Diluent	1.563
P7	EIA Diluent	0.000



- **Biotinylated Human Lp(a) Antibody (50x):** Spin down the antibody briefly and dilute the desired amount of the antibody 1:50 with EIA Diluent. Any remaining solution should be frozen at -20°C.
- **Wash Buffer Concentrate (20x):** If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute the Wash Buffer Concentrate 1:20 with reagent grade water.
- **SP Conjugate (100x):** Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 1:100 with EIA Diluent. Any remaining solution should be frozen at -20°C.

## Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human Lp(a) Standard or sample per well. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash five times with 200 µl of Wash Buffer manually. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a machine, wash six times with 300 µl of Wash Buffer and then invert the plate, decanting the contents; hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Lp(a) Antibody to each well and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of Streptavidin-Peroxidase Conjugate to each well and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate per well and incubate for 10 minutes or till the optimal blue color density develops. Gently tap plate to ensure thorough mixing and break the bubbles in the well with pipette tip.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow.
- Read the absorbance on a microplate reader at a wavelength of 450 nm **immediately**. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points

after stopping the reaction for about 10 minutes, which will reduce the readings.

## Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The best-fit line can be determined by regression analysis using log-log or four-parameter logistic curve-fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

## Typical Data


- The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	50.00	2.119 1.983	2.051
P2	25.00	1.442 1.410	1.426
P3	12.50	0.792 0.764	0.778
P4	6.250	0.480 0.452	0.466
P5	3.125	0.297 0.271	0.284
P6	1.563	0.236 0.225	0.231
P7	0.000	0.190 0.187	0.188
<b>Sample: Pool Normal, Sodium Citrate Plasma (8000x)</b>		0.709 0.724	0.716

## Standard Curve

- The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

### Human Lp(a) Standard Curve



### Reference Value

- Normal human Lp(a) plasma levels range from 60 to 180 µg/ml.
- Human plasma and serum samples from healthy adults were tested (n=40). On average, Lp(a) level was 98 µg/ml.

Sample	n	Average Value (µg/ml)
Human Pool Normal Plasma	10	95
Human Normal Plasma	20	89
Human Pool Normal Serum	10	110

### Performance Characteristics

- The minimum detectable dose of Lp(a) as calculated by 2SD from the mean of a zero standard was established to be 0.8 ng/ml.
- Intra-assay precision was determined by testing replicates of three plasma samples in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

Sample	Intra-Assay Precision			Inter-Assay Precision		
	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	4.1%	4.3%	4.5%	10.0%	9.9%	9.8%
Average CV (%)	4.3%			9.9%		

## Spiking Recovery

- Recovery was determined by spiking two plasma samples with different Lp(a) concentrations.

Sample	Unspiked Sample (ng/ml)	Spike (ng/ml)	Expected	Observed	Recovery (%)
1	7.5	2.0	9.5	9.3	98%
		7.5	15.0	13.7	91%
		15.0	22.5	23.0	102%
2	15.8	2.0	17.8	19.1	107%
		7.5	23.3	24.7	106%
		15.0	30.8	32.4	105%
<b>Average Recovery (%)</b>					<b>101%</b>

## Linearity

- Plasma and serum samples were serially-diluted to test for linearity.

Sample Dilution	Average Percentage of Expected Value (%)	
	Plasma	Serum
1:4000	104%	95%
1:8000	98%	99%
1:16000	101%	106%

## Cross-Reactivity

Species	Cross Reactivity (%)
Canine	None
Bovine	None
Monkey	<10%
Mouse	None
Rat	None
Swine	None
Rabbit	None
Human	100%
Proteins	Cross Reactivity (%)
Apo B	10%

- No significant cross reactivity with human ApoA-I, ApoA-II, ApoC-I, ApoC-III, or ApoE.

## Troubleshooting

Issue	Causes	Course of Action
Low Precision	Use of expired components	<ul style="list-style-type: none"> <li>• Check the expiration date listed before use.</li> <li>• Do not interchange components from different lots.</li> </ul>
	Improper wash step	<ul style="list-style-type: none"> <li>• Check that the correct wash buffer is being used.</li> <li>• Check that all wells are dry after aspiration.</li> <li>• Check that the microplate washer is dispensing properly.</li> <li>• If washing by pipette, check for proper pipetting technique.</li> </ul>
	Splashing of reagents while loading wells	<ul style="list-style-type: none"> <li>• Pipette properly in a controlled and careful manner.</li> </ul>
	Inconsistent volumes loaded into wells	<ul style="list-style-type: none"> <li>• Pipette properly in a controlled and careful manner.</li> <li>• Check pipette calibration.</li> <li>• Check pipette for proper performance.</li> </ul>
	Insufficient mixing of reagent dilutions	<ul style="list-style-type: none"> <li>• Thoroughly agitate the lyophilized components after reconstitution.</li> <li>• Thoroughly mix dilutions.</li> </ul>
	Improperly sealed microplate	<ul style="list-style-type: none"> <li>• Check the microplate pouch for proper sealing.</li> <li>• Check that the microplate pouch has no punctures.</li> <li>• Check that three desiccants are inside the microplate pouch prior to sealing.</li> </ul>
Unexpectedly Low or High Signal Intensity	Microplate was left unattended between steps	<ul style="list-style-type: none"> <li>• Each step of the procedure should be performed uninterrupted.</li> </ul>
	Omission of step	<ul style="list-style-type: none"> <li>• Consult the provided procedure for complete list of steps.</li> </ul>
	Steps performed in incorrect order	<ul style="list-style-type: none"> <li>• Consult the provided procedure for the correct order.</li> </ul>
	Insufficient amount of reagents added to wells	<ul style="list-style-type: none"> <li>• Check pipette calibration.</li> <li>• Check pipette for proper performance.</li> </ul>
	Wash step was skipped	<ul style="list-style-type: none"> <li>• Consult the provided procedure for all wash steps.</li> </ul>
	Improper wash buffer	<ul style="list-style-type: none"> <li>• Check that the correct wash buffer is being used.</li> </ul>
	Improper reagent preparation	<ul style="list-style-type: none"> <li>• Consult reagent preparation section for the correct dilutions of all reagents.</li> </ul>
Insufficient or prolonged incubation periods	<ul style="list-style-type: none"> <li>• Consult the provided procedure for correct incubation time.</li> </ul>	
Deficient Standard Curve Fit	Non-optimal sample dilution	<ul style="list-style-type: none"> <li>• Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay.</li> <li>• Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay.</li> <li>• User should determine the optimal dilution factor for samples.</li> </ul>
	Contamination of reagents	<ul style="list-style-type: none"> <li>• A new tip must be used for each addition of different samples or reagents during the assay procedure.</li> </ul>
	Contents of wells evaporate	<ul style="list-style-type: none"> <li>• Verify that the sealing film is firmly in place before placing the assay in the incubator or at room temperature.</li> </ul>
	Improper pipetting	<ul style="list-style-type: none"> <li>• Pipette properly in a controlled and careful manner.</li> <li>• Check pipette calibration.</li> <li>• Check pipette for proper performance.</li> </ul>

	Insufficient mixing of reagent dilutions	<ul style="list-style-type: none"> <li>• Thoroughly agitate the lyophilized components after reconstitution.</li> <li>• Thoroughly mix dilutions.</li> </ul>
--	--	--

## References

- (1) Wild SH *et al.* (1997) *Arteriosclerosis, Thrombosis, and Vascular Biology* 17:239-245
- (2) Salonen EM *et al.* (1989) *EMBO J.* 8:4035-4040
- (3) Gaubatz JW *et al.* (1983) *J. Biol. Chem.* 258:4582-4589
- (4) Eaton DL *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3224
- (5) McLean JW *et al.* (1987) *Nature* 330:132
- (6) Hajjar KA *et al.* (1989) *Nature* 339:303-305
- (7) Utermann G (1989) *Science* 246:904-910
- (8) Schreiner PJ *et al.* (1993) *Arterioscler. Thromb. Vasc. Biol.* 13:826-833
- (9) Marcovina SM *et al.* (2000) *Clin. Chem.* 46:1956-1967
- (10) Rhoads GG *et al.* (1986) *JAMA* 256:2540-2544
- (11) Hoefler G. *et al.* (1988) *Arteriosclerosis* 8:398-401

Version 2.4